US20030144875A1 - EEG prediction method for medication response - Google Patents

EEG prediction method for medication response Download PDF

Info

Publication number
US20030144875A1
US20030144875A1 US09/930,632 US93063201A US2003144875A1 US 20030144875 A1 US20030144875 A1 US 20030144875A1 US 93063201 A US93063201 A US 93063201A US 2003144875 A1 US2003144875 A1 US 2003144875A1
Authority
US
United States
Prior art keywords
patient
database
eeg
medications
nupharm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/930,632
Inventor
Stephen Suffin
W. Emory
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US09/930,632 priority Critical patent/US20030144875A1/en
Priority to US10/193,735 priority patent/US7177675B2/en
Publication of US20030144875A1 publication Critical patent/US20030144875A1/en
Priority to US11/054,762 priority patent/US8239013B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/369—Electroencephalography [EEG]
    • A61B5/372—Analysis of electroencephalograms
    • A61B5/374—Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
    • A61B5/165—Evaluating the state of mind, e.g. depression, anxiety
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F21/00—Security arrangements for protecting computers, components thereof, programs or data against unauthorised activity
    • G06F21/60—Protecting data
    • G06F21/62—Protecting access to data via a platform, e.g. using keys or access control rules
    • G06F21/6218—Protecting access to data via a platform, e.g. using keys or access control rules to a system of files or objects, e.g. local or distributed file system or database
    • G06F21/6245—Protecting personal data, e.g. for financial or medical purposes
    • G06F21/6254—Protecting personal data, e.g. for financial or medical purposes by anonymising data, e.g. decorrelating personal data from the owner's identification
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H80/00—ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Definitions

  • antidepressant class medications anticonvulsant class medications, combinations of psychostimulant and antidepressant class medications, combinations of anticonvulsant and antidepressant class medications, combinations of psychostimulant, antidepressant, and anticonvulsant class medications.
  • the present invention also includes a method for computerized generation of clinical reports that integrates interpretive information from medical professionals with results of medication responsivity evaluation.
  • FIG. 1 illustrates a method of the present invention where: step 1 of FIG. 1 corresponds to elements 1 and 2 of the invention described below; step 2 corresponds to elements 3 , 4 , and 3 ; step 3 to elements 6 and 7 ; step 4 to element 8 ; and step 5 to elements 9 and 10 .
  • the EEG is recorded using electrodes placed on the patient's scalp, and the EEG data is stored in a digital format using a standardized protocol available on one of a number of commercially available instruments (current manufacturers include Cadwell Laboratories, Bio-Logic Systems Corp., Nicolet Biomedical, Oxford Instruments, among others).
  • the International 10-20 System convention is used for determining the location of electrodes placed on the scalp. It is the responsibility of the recording facility to collect data in accordance with procedural specifications.
  • Insulin, thyroid, estrogen, progesterone and other hormone replacement agents are not excluded. Some cardiac agents are included in the reference population of after the age of fifty-five.
  • UDS Urine Drug Screen
  • the digital EEG data computer file is packaged along with additional patient identifying information using packaging and transmission software.
  • the patient information includes:
  • Packaging refers to compression of the computer file and encryption of the file so that it cannot be opened or examined by anyone other than at the processing center.
  • the data transfer is rigorously secured to protect the confidentiality of patient records.
  • the EEG files are encrypted at the recording facility with a key known only to processing center.
  • the patient ID is transformed using a algorithm so that even in the case of mail routing error there is no way to associate the data with an individual.
  • the data is compressed and protected with an additional password and data files are transmitted to a secure site. These steps mean that the patient data are protected against even purposeful attempts to intercept and read them.
  • the computer operating system preferred to run the packaging and report transmission software is currently Microsoft Windows 95/98.
  • the following hardware and software is preferred:
  • Operating System Windows 95 or Windows 98
  • Monitor and Video Card capable of displaying 256 colors.
  • RAM 16 MB
  • CD-ROM Drive if installing from CD-ROM
  • the computer file is transferred off-hours using standard commercially available file transfer protocols (FTP) via the Internet, to a designated processing site.
  • FTP file transfer protocol
  • a special feature of the packaging and transmission software exists to allow immediate transfer of files for priority reporting if requested.
  • the processing site monitors the transfer in order to detect the arrival of new computer files. When a new file is received, it is forwarded for professional interpretation, if requested, and specialized report generation.
  • the first stage of analysis includes computations that extract a standard set of features from the EEG.
  • Quantitative spectral analysis provides commonly used measures of EFG power and relative power. Power is the square of amplitude; amplitude units are in microvolts ( ⁇ V), power units are microvolts squared( ⁇ V 2 ).
  • Relative power is a measure of the proportion of power in a given frequency band compared to the total band power at a given electrode. Frequency bands are defined as delta, 0.5-2.5 Hz.; theta, 2.5-7.5 Hz.; alpha, 7.5-12.5 Hz., and beta, 12.5-32 Hz. The total band is 0.5 to 32 Hz.
  • EEG coherence a commonly used measure of the similarity of activity for a pair of two scalp electrodes, also is extracted by spectral analysis for all interhemispheric and intrahemispheric sets of electrode pairs, for each frequency band as defined above.
  • the third stage of processing involves medication response prediction using the patient database(database #2). This prediction is made by first identifying the pattern of EEG deviations from the reference database. Individual patient deviation is then compared with the characteristic features of the population of patients whose medications and treatment outcomes are known. A rule-based classifier is applied to estimate the likelihood that a patient EEG contains a pattern known to be responsive to a given agent, class of agents, or combination of agents or classes of agents.
  • the EEG variables currently used by the classifier are shown in Tables 1-4, below.
  • a formal report for the referring clinician is generated.
  • the report is returned in a format that cannot be modified by the client (Adobe Systems, Inc., “portable document format”, or “PDF”).
  • PDF Portable document format
  • This report contains certain elements as specifically requested by the referring clinician. These elements may include a professional medical interpretation of the digital EEG tracing, a presentation of selected features extracted by quantitative EEG analysis, a presentation of deviations from the Neurometric database, and a statement of the likelihood of favorable pharmacotherapeutic outcome based on comparison with patients having similar EEG features in the patient database #2.
  • the treating physician is responsible for any medication selection, titrating of dosage and monitoring the patient for side effects and is instructed to incorporate results of reports with the psychiatric assessment to develop into an overall clinical treatment plan.
  • the report is returned and may be downloaded by the client on a regular schedule, using the packaging and transmission software for viewing and printing the report by the client at the recording site.
  • PDF files are opened and displayed using an interface to Adobe Acrobat Reader (TM) software. Reports may be printed on any operating system compatible printer.

Abstract

The present invention includes a system and method for computerized analysis of a patient's electroencephalogram (EEG) recorded by electrodes placed on the scalp, for the purpose of predicting patient response to medications and therapeutic agents commonly used in psychiatric practice. The prediction of the responses to medications (adverse, no effect, favorable outcome) is an important problem in the clinical practice of psychiatry. A growing number of therapeutic agents are available to the clinician but these agents generate variable responses when prescribed based solely on the patient's history and current symptoms. The present invention is used by physicians to improve patient outcome by selecting agents most likely to be effective for a given patient, using a standardized analysis of the digitized EEG and comparison of individual patient EEC data to a particular database of similar patients whose clinical outcome to pharmacotherapy is known.

Description

  • [0001]
    Figure US20030144875A1-20030731-P00999
    antidepressant class medications, anticonvulsant class medications, combinations of psychostimulant and antidepressant class medications, combinations of anticonvulsant and antidepressant class medications, combinations of psychostimulant, antidepressant, and anticonvulsant class medications.
  • The present invention also includes a method for computerized generation of clinical reports that integrates interpretive information from medical professionals with results of medication responsivity evaluation.[0002]
    • BRIEF DESCRIPTION OF THE FIGURES
  • The present invention may be understood more fully by reference to the following detailed description of the preferred embodiment of the present invention, illustrative examples of specific embodiments of the invention and the appended figures in which [0003]
  • FIG. 1 illustrates a method of the present invention where: step [0004] 1 of FIG. 1 corresponds to elements 1 and 2 of the invention described below; step 2 corresponds to elements 3, 4, and 3; step 3 to elements 6 and 7; step 4 to element 8; and step 5 to elements 9 and 10.
    • DETAILED DESCRIPTION OF THE INVENTION
  • More specifically, the following steps are employed: [0005]
  • 1) The EEG is recorded using electrodes placed on the patient's scalp, and the EEG data is stored in a digital format using a standardized protocol available on one of a number of commercially available instruments (current manufacturers include Cadwell Laboratories, Bio-Logic Systems Corp., Nicolet Biomedical, Oxford Instruments, among others). The International 10-20 System convention is used for determining the location of electrodes placed on the scalp. It is the responsibility of the recording facility to collect data in accordance with procedural specifications. [0006]
  • 2) The following patient criteria apply: [0007]
  • a) Patient must have received a psychiatric diagnosis as specified in the Diagnostic and Statistical Manual, currently the Fourth Edition (DSM-IV). [0008]
  • b) Ages between six and ninety. [0009]
  • c) Patient is taking no medications. All medications potentially influence the EEG and must be discontinued or avoided for seven half-lives prior to baseline EBG examination. This includes “over the counter” sleeping pills, pain medication, nutritional health supplements and mega-vitamins. [0010]
  • d) Insulin, thyroid, estrogen, progesterone and other hormone replacement agents are not excluded. Some cardiac agents are included in the reference population of after the age of fifty-five. [0011]
  • e) Patients with any of the characteristics listed below are not suitable for prediction of medication responsivity based on EEG analysis: [0012]
  • (i) intramuscular depo-neuroleptic therapy within the preceding twelve months [0013]
  • (ii) a history of craniotomy with or without metal prostheses [0014]
  • (iii) a history of cerebrovascular accident [0015]
  • (iv) spikes or extreme low voltage on the conventional EEG [0016]
  • (v) a current diagnosis of seizure disorder [0017]
  • (vi) a diagnosis of dementia [0018]
  • (vii) mental retardation [0019]
  • (viii) current use of marijuana, cocaine, hallucinogens or other drugs of abuse [0020]
  • (ix) inability to remain medication-free and drug-free for seven half-lives of the current agent(s) prior to EEG recording [0021]
  • (x) significant abnormality of the CBC, chemistry or thyroid panel with TSH until corrected [0022]
  • f) A “positive” Urine Drug Screen (UDS) interferes with medication prediction methods. Studies are processed only if the UDS is negative just prior to recording the digital EEG. [0023]
  • 3) The digital EEG data computer file is packaged along with additional patient identifying information using packaging and transmission software. The patient information includes: [0024]
  • a) name [0025]
  • b) date of birth [0026]
  • c) referring physician [0027]
  • d) handedness [0028]
  • e) height [0029]
  • f) weight [0030]
  • g) date of test [0031]
  • h) patient ID (social security number) [0032]
  • Packaging refers to compression of the computer file and encryption of the file so that it cannot be opened or examined by anyone other than at the processing center. The data transfer is rigorously secured to protect the confidentiality of patient records. The EEG files are encrypted at the recording facility with a key known only to processing center. The patient ID is transformed using a algorithm so that even in the case of mail routing error there is no way to associate the data with an individual. The data is compressed and protected with an additional password and data files are transmitted to a secure site. These steps mean that the patient data are protected against even purposeful attempts to intercept and read them. [0033]
  • The transmittal of the EEG file and related patient information is tracked as it is packaged, sent, processed, and returned. All log entries include dates and times calibrated to GMT. [0034]
  • The computer operating system preferred to run the packaging and report transmission software is currently Microsoft Windows 95/98. The following hardware and software is preferred: [0035]
  • Hardware Requirements [0036]
  • Operating System: Windows 95 or Windows 98 [0037]
  • Processor: 486, 133 MHZ. [0038]
  • Monitor and Video Card capable of displaying 256 colors. [0039]
  • Disk Space: 35 MB [0040]
  • RAM: 16 MB [0041]
  • CD-ROM Drive if installing from CD-ROM [0042]
  • Modem: 33.6 KBaud [0043]
  • Internet Connection with approved Internet Service Provider [0044]
  • Software Requirements [0045]
  • Adobe Acrobat Reader Version 3.01 [0046]
  • Microsoft Internet Explorer 4.0 or above [0047]
  • The packaging and transmission software [0048]
  • 4) The computer file is transferred off-hours using standard commercially available file transfer protocols (FTP) via the Internet, to a designated processing site. A special feature of the packaging and transmission software exists to allow immediate transfer of files for priority reporting if requested. The processing site monitors the transfer in order to detect the arrival of new computer files. When a new file is received, it is forwarded for professional interpretation, if requested, and specialized report generation. [0049]
  • 5) The file is decompressed and decrypted at the processing site. Experienced technical and professional personnel then review the EEG signals and sections of the recording identified as containing signals generated by extracerebral sources are deleted from subsequent analyses. The samples of EEG selected for inclusion in analysis are then passed to the first stage of analysis. [0050]
  • 6) The first stage of analysis includes computations that extract a standard set of features from the EEG. Quantitative spectral analysis provides commonly used measures of EFG power and relative power. Power is the square of amplitude; amplitude units are in microvolts (μV), power units are microvolts squared(μV[0051] 2). Relative power is a measure of the proportion of power in a given frequency band compared to the total band power at a given electrode. Frequency bands are defined as delta, 0.5-2.5 Hz.; theta, 2.5-7.5 Hz.; alpha, 7.5-12.5 Hz., and beta, 12.5-32 Hz. The total band is 0.5 to 32 Hz.
  • EEG coherence, a commonly used measure of the similarity of activity for a pair of two scalp electrodes, also is extracted by spectral analysis for all interhemispheric and intrahemispheric sets of electrode pairs, for each frequency band as defined above. [0052]
  • Commonly used measures of peak frequency within each defined frequency band are computed. [0053]
  • Combinations of power and coherence measures over defined sets of scalp electrodes are also computed. [0054]
  • 7) Features extracted from individual EEG data by quantitative spectral and statistical analysis are further compared to two distinct databases. In the second stage of analysis, Z-scores representing deviations from a nonsymptomatic reference population are computed. This reference population, often referred to as the “Neurometric” database, contains 2082 quantitative EEG measures including absolute power, relative power, coherence, symmetry, and mean frequency of the delta, theta, alpha and beta frequency bands of the EEG at every electrode position of the International 10-20 System for individuals from 6 to 92 years (database #1). The z-score value obtained by comparison of individual's data to the age appropriate subset of the database represents the patient's statistical deviation from the reference database. [0055]
  • 8) The third stage of processing involves medication response prediction using the patient database(database #2). This prediction is made by first identifying the pattern of EEG deviations from the reference database. Individual patient deviation is then compared with the characteristic features of the population of patients whose medications and treatment outcomes are known. A rule-based classifier is applied to estimate the likelihood that a patient EEG contains a pattern known to be responsive to a given agent, class of agents, or combination of agents or classes of agents. The EEG variables currently used by the classifier are shown in Tables 1-4, below. [0056]
    Column Column
    Heading Description of Abbreviation Heading Description of Abbreviation
    Table 1 Table 2
    RMAD Relative power monopolar FMAD Frequency monopolar
    anterior delta anterior delta
    RMPD posterior data FMPD posterior delta
    RMAT anterior theta FMAT anterior theta
    RMPT posterior theta FMPT posterior theta
    RMAA Anterior alpha FMAA anterior alpha
    RMPA Posterior alpha FMPA posterior alpha
    RMAB Anterior beta FMAB anterior beta
    RMPB posterior beta FMPB posterior beta
    CEAD Coherence interhemispheric AADL Asymmetry intrahemispheric
    anterior delta delta - left
    CEPD Posterior delta AADR delta - right
    CEAT anterior theta AATL theta - left
    CEPT posterior theta AATR theta - right
    CEAA anterior alpha AAAL alpha - left
    CEPA Posterior alpha AAAR alpha - right
    CEAB Anterior beta AABL beta - left
    CEPB posterior beta AABR beta - right
    Table 3 Table 4
    AED Asymmetry monopolar CEBD Coherence interhemispheric bipolar
    interhemispheric delta delta
    AFT Theta CEBT Theta
    AEA Alpha CEBA Alpha
    AEB Beta CEBB Beta
    AEBD Asymmetry bipolar RBDL Relative power bipolar delta left
    interhemispheric delta
    AEBT Theta RBDR Delta - right
    AEBA Alpha RBTL Theta - left
    AEBB Beta RBTR Theta - right
    CADL Coherence intrahemispheric RBAL Alpha - left
    delta - left
    CADR Delta - right RBAR Alpha - right
    CATL Theta - left RBBL Beta - left
    CATR Theta - right RBBR Beta - right
    CAAL Alpha - left
    CAAR Alpha - right
    CABL Beta - left
    CABR Beta - right
  • 9) A formal report for the referring clinician is generated. The report is returned in a format that cannot be modified by the client (Adobe Systems, Inc., “portable document format”, or “PDF”). This report contains certain elements as specifically requested by the referring clinician. These elements may include a professional medical interpretation of the digital EEG tracing, a presentation of selected features extracted by quantitative EEG analysis, a presentation of deviations from the Neurometric database, and a statement of the likelihood of favorable pharmacotherapeutic outcome based on comparison with patients having similar EEG features in the patient database #2. The treating physician is responsible for any medication selection, titrating of dosage and monitoring the patient for side effects and is instructed to incorporate results of reports with the psychiatric assessment to develop into an overall clinical treatment plan. [0057]
  • 10) The report is returned and may be downloaded by the client on a regular schedule, using the packaging and transmission software for viewing and printing the report by the client at the recording site. PDF files are opened and displayed using an interface to Adobe Acrobat Reader (TM) software. Reports may be printed on any operating system compatible printer. [0058]
  • 11) Follow up EEG recordings can then be used to track changes produced by administration of medications by repeating the entire process outlined above. For follow up studies, the patient also is interviewed by the treating physician and Clinical Global Improvement (CGI) is scored. A score of −1 indicates an adverse effect, 0 no improvement, 1 minimal or mild improvement, 2 moderate improvement, and 3 marked improvement or remission of symptoms. The CGI scores are sent to the processing center and are reported along with changes, expressed as difference scores, on variables shown in Tables 1-4 above. [0059]
  • The invention described and claimed herein is not to be limited in scope by the preferred embodiments herein disclosed, since these embodiments are intended as illustrations of several aspects of the invention. Any equivalent embodiments are intended to be within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. [0060]
  • The entire disclosures of references cited herein are incorporated herein, in their entireties, for all purposes. [0061]
  • Citation or identification of a reference in this application or in connection with this application shall not be construed that such reference is available as prior art to the present invention. [0062]

Claims (8)

We claim:
1. A unique system for compressing, encrypting, tracking, and securely transmitting digital EEG data and associated patient identifying information via the Internet from a remote site to a Report Processing Center, and including the electronic return of a report summarizing results of proprietary analyses and database comparison all without requiring telephonic transmission.
2. Identification of a set of univariate and multivariate EEG features that when observed in a patient diagnosed with a psychiatric disorder, can be used with NuPharm Database's particular rule-based classifier to predict a favorable clinical responsive to psychostimulant class medications.
3. Identification of a set of univariate and multivariate EEG features that when observed in a patient diagnosed with a psychiatric disorder, can be used with NuPharm Database's particular rule-based classifier to predict a favorable clinical responsive to antidepressant class medications.
4. Identification of a set of univariate and multivariate EEG features that when observed in a patient diagnosed with a psychiatric disorder, can be used with NuPharm Database's particular rule-based classifier to predict a favorable clinical response to anticonvulsant class medications.
5. Identification of a set of univariate and multivariate EEG features that when observed in a patient diagnosed with a psychiatric disorder, can be used with NuPharm Database's particular rule-based classifier to predict a favorable clinical responsive to a combination of psychostimulant and antidepressant class medications.
6. Identification of a set of univariate and multivariate EEG features that when observed in a patient diagnosed with a psychiatric disorder, can be used with NuPharm Database's particular rule-based classifier to predict a favorable clinical responsive to a combination of anticonvulsant and antidepressant class medications.
7. Identification of a set of univariate and multivariate EEG features that when observed in a patient diagnosed with a psychiatric disorder, can be used with NuPharm Database's particular rule-based classifier to predict a favorable clinical response to a combination of psychostimulant, antidepressant, and anticonvulsant class medications.
8. A method for computerized generation of clinical reports that integrates interpretive information from medical professionals with results of medication responsivity evaluation according to claim 2.
US09/930,632 1997-09-06 2001-08-15 EEG prediction method for medication response Abandoned US20030144875A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US09/930,632 US20030144875A1 (en) 1997-09-06 2001-08-15 EEG prediction method for medication response
US10/193,735 US7177675B2 (en) 2000-02-09 2002-07-11 Electroencephalography based systems and methods for selecting therapies and predicting outcomes
US11/054,762 US8239013B2 (en) 1997-09-06 2005-02-10 EEG prediction method for medication response

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5805297P 1997-09-06 1997-09-06
US14859198A 1998-09-04 1998-09-04
US09/930,632 US20030144875A1 (en) 1997-09-06 2001-08-15 EEG prediction method for medication response

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14859198A Continuation 1997-09-06 1998-09-04

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/193,735 Continuation-In-Part US7177675B2 (en) 2000-02-09 2002-07-11 Electroencephalography based systems and methods for selecting therapies and predicting outcomes
US11/054,762 Continuation US8239013B2 (en) 1997-09-06 2005-02-10 EEG prediction method for medication response

Publications (1)

Publication Number Publication Date
US20030144875A1 true US20030144875A1 (en) 2003-07-31

Family

ID=46280055

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/930,632 Abandoned US20030144875A1 (en) 1997-09-06 2001-08-15 EEG prediction method for medication response
US11/054,762 Expired - Lifetime US8239013B2 (en) 1997-09-06 2005-02-10 EEG prediction method for medication response

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/054,762 Expired - Lifetime US8239013B2 (en) 1997-09-06 2005-02-10 EEG prediction method for medication response

Country Status (1)

Country Link
US (2) US20030144875A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050165323A1 (en) * 1999-10-07 2005-07-28 Lamont, Llc. Physiological signal monitoring apparatus and method
US20050240146A1 (en) * 2004-04-27 2005-10-27 Nash John E Thrombectomy and soft debris removal device
US20080097499A1 (en) * 2004-04-27 2008-04-24 Nash John E Thrombectomy and soft debris removal device
US20090312663A1 (en) * 2008-06-13 2009-12-17 New York University System and Method for Neurometric Analysis
CN103976740A (en) * 2014-05-23 2014-08-13 清华大学 Network environment-oriented electroencephalogram identification system and network environment-oriented electroencephalogram identification method
CN109846477A (en) * 2019-01-29 2019-06-07 北京工业大学 A kind of brain electricity classification method based on frequency band attention residual error network
CN110960233A (en) * 2019-11-21 2020-04-07 唐延智 Depression state detection method and system based on brain waves
US20200163573A1 (en) * 2010-01-06 2020-05-28 Evoke Neurosceince, Inc. Electrophysiology measurement and training and remote databased and data analysis measurement method and system

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007143663A2 (en) * 2006-06-05 2007-12-13 The Regents Of The University Of California Quantitative eeg method to identify individuals at risk for adverse antidepressant effects
WO2009079366A2 (en) * 2007-12-18 2009-06-25 New York University System and method for assessing efficacy of therapeutic agents
US20110160607A1 (en) * 2007-12-18 2011-06-30 New York University QEED-Guided Selection and Titration of Psychotropic Medications
US8442626B2 (en) 2010-06-21 2013-05-14 Aleksandrs Zavoronkovs Systems and methods for communicating with a computer using brain activity patterns
US20120230560A1 (en) * 2011-03-09 2012-09-13 Pattern Analysis, Inc. Scheme for detection of fraudulent medical diagnostic testing results through image recognition
CN107967182A (en) * 2016-10-19 2018-04-27 南京航空航天大学 The end-to-end data flow consistency verification methods of AADL

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201224A (en) * 1978-12-29 1980-05-06 Roy John E Electroencephalographic method and system for the quantitative description of patient brain states
US5083571A (en) * 1988-04-18 1992-01-28 New York University Use of brain electrophysiological quantitative data to classify and subtype an individual into diagnostic categories by discriminant and cluster analysis
US5176145A (en) * 1990-04-25 1993-01-05 Ryback Ralph S Method for diagnosing a patient to determine whether the patient suffers from limbic system dysrhythmia
US5230346A (en) * 1992-02-04 1993-07-27 The Regents Of The University Of California Diagnosing brain conditions by quantitative electroencephalography
US5267570A (en) * 1992-12-30 1993-12-07 Preston Myra S Method of diagnosing and treating chronic fatigue syndrome
US5357976A (en) * 1989-10-30 1994-10-25 Genquan Feng Method of and arrangement for diagnosing brain disease
US5445162A (en) * 1993-08-27 1995-08-29 Beth Israel Hospital Association Apparatus and method for recording an electroencephalogram during magnetic resonance imaging
US5447166A (en) * 1991-09-26 1995-09-05 Gevins; Alan S. Neurocognitive adaptive computer interface method and system based on on-line measurement of the user's mental effort
US5730146A (en) * 1991-08-01 1998-03-24 Itil; Turan M. Transmitting, analyzing and reporting EEG data
US5871517A (en) * 1997-01-15 1999-02-16 Somatics, Inc. Convulsive therapy apparatus to stimulate and monitor the extent of therapeutic value of the treatment
US5873823A (en) * 1995-01-27 1999-02-23 Eidelberg; David Markers for use in screening patients for nervous system dysfunction and a method and apparatus for using same
US5884626A (en) * 1994-09-02 1999-03-23 Toyota Jidosha Kabushiki Kaisha Apparatus and method for analyzing information relating to physical and mental condition
US6021346A (en) * 1997-11-13 2000-02-01 Electronics And Telecommunications Research Institute Method for determining positive and negative emotional states by electroencephalogram (EEG)
US6061593A (en) * 1997-10-27 2000-05-09 Neuropace, Inc. EEG d-c voltage shift as a means for detecting the onset of a neurological event
US6195576B1 (en) * 1998-03-09 2001-02-27 New York University Quantitative magnetoencephalogram system and method
US6223074B1 (en) * 1999-08-10 2001-04-24 Thuris Corporation Method and computer program product for assessing neurological conditions and treatments using evoked response potentials
US20010020137A1 (en) * 1999-08-10 2001-09-06 Richard Granger Method and computer program product for assessing neurological conditions and treatments using evoked response potentials
US6434419B1 (en) * 2000-06-26 2002-08-13 Sam Technology, Inc. Neurocognitive ability EEG measurement method and system

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4533346A (en) * 1979-06-26 1985-08-06 Pharmacontrol Corporation System for automatic feedback-controlled administration of drugs
US4846190A (en) * 1983-08-23 1989-07-11 John Erwin R Electroencephalographic system data display
US4632122A (en) * 1985-04-24 1986-12-30 Johansson Nils E Method and apparatus for conducting brain function diagnostic test
US5279305A (en) * 1992-08-06 1994-01-18 Pedifutures, Inc. Electroencephalograph incorporating at least one wireless link
US5699808A (en) * 1994-02-07 1997-12-23 New York University EEG operative and post-operative patient monitoring system and method
IT1280806B1 (en) * 1995-01-26 1998-02-11 Ist Trentino Di Cultura COMPRESSION PROCEDURE FOR EEG SIGNALS.
US5755230A (en) * 1995-09-18 1998-05-26 Cleveland Medical Devices Inc. Wireless EEG system for effective auditory evoked response
US5775330A (en) * 1996-07-22 1998-07-07 Battelle Memorial Institute Neurometric assessment of intraoperative anesthetic
US5791342A (en) * 1996-09-03 1998-08-11 Telediagnostics Systems, Inc. Medical data transmission system

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201224A (en) * 1978-12-29 1980-05-06 Roy John E Electroencephalographic method and system for the quantitative description of patient brain states
US5083571A (en) * 1988-04-18 1992-01-28 New York University Use of brain electrophysiological quantitative data to classify and subtype an individual into diagnostic categories by discriminant and cluster analysis
US5357976A (en) * 1989-10-30 1994-10-25 Genquan Feng Method of and arrangement for diagnosing brain disease
US5176145A (en) * 1990-04-25 1993-01-05 Ryback Ralph S Method for diagnosing a patient to determine whether the patient suffers from limbic system dysrhythmia
US5730146A (en) * 1991-08-01 1998-03-24 Itil; Turan M. Transmitting, analyzing and reporting EEG data
US5447166A (en) * 1991-09-26 1995-09-05 Gevins; Alan S. Neurocognitive adaptive computer interface method and system based on on-line measurement of the user's mental effort
US5230346A (en) * 1992-02-04 1993-07-27 The Regents Of The University Of California Diagnosing brain conditions by quantitative electroencephalography
US5267570A (en) * 1992-12-30 1993-12-07 Preston Myra S Method of diagnosing and treating chronic fatigue syndrome
US5445162A (en) * 1993-08-27 1995-08-29 Beth Israel Hospital Association Apparatus and method for recording an electroencephalogram during magnetic resonance imaging
US5884626A (en) * 1994-09-02 1999-03-23 Toyota Jidosha Kabushiki Kaisha Apparatus and method for analyzing information relating to physical and mental condition
US5873823A (en) * 1995-01-27 1999-02-23 Eidelberg; David Markers for use in screening patients for nervous system dysfunction and a method and apparatus for using same
US5871517A (en) * 1997-01-15 1999-02-16 Somatics, Inc. Convulsive therapy apparatus to stimulate and monitor the extent of therapeutic value of the treatment
US6061593A (en) * 1997-10-27 2000-05-09 Neuropace, Inc. EEG d-c voltage shift as a means for detecting the onset of a neurological event
US6021346A (en) * 1997-11-13 2000-02-01 Electronics And Telecommunications Research Institute Method for determining positive and negative emotional states by electroencephalogram (EEG)
US6195576B1 (en) * 1998-03-09 2001-02-27 New York University Quantitative magnetoencephalogram system and method
US6223074B1 (en) * 1999-08-10 2001-04-24 Thuris Corporation Method and computer program product for assessing neurological conditions and treatments using evoked response potentials
US20010020137A1 (en) * 1999-08-10 2001-09-06 Richard Granger Method and computer program product for assessing neurological conditions and treatments using evoked response potentials
US6434419B1 (en) * 2000-06-26 2002-08-13 Sam Technology, Inc. Neurocognitive ability EEG measurement method and system

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050165323A1 (en) * 1999-10-07 2005-07-28 Lamont, Llc. Physiological signal monitoring apparatus and method
US9808277B2 (en) 2004-04-27 2017-11-07 The Spectranetics Corporation Thrombectomy and soft debris removal device
US20050240146A1 (en) * 2004-04-27 2005-10-27 Nash John E Thrombectomy and soft debris removal device
US20070282303A1 (en) * 2004-04-27 2007-12-06 Nash John E Thrombectomy and soft debris removal device
US20080097499A1 (en) * 2004-04-27 2008-04-24 Nash John E Thrombectomy and soft debris removal device
US7666161B2 (en) 2004-04-27 2010-02-23 The Spectranetics Corporation Thrombectomy and soft debris removal device
US20100145259A1 (en) * 2004-04-27 2010-06-10 The Spectranetics Corporation Thrombectomy and soft debris removal device
US7959608B2 (en) 2004-04-27 2011-06-14 The Spectranetics Corporation Thrombectomy and soft debris removal device
US7976528B2 (en) 2004-04-27 2011-07-12 The Spectranetics, Corp. Thrombectomy and soft debris removal device
US10517633B2 (en) 2004-04-27 2019-12-31 The Spectranetics Corporation Thrombectomy and soft debris removal device
US8920402B2 (en) 2004-04-27 2014-12-30 The Spectranetics Corporation Thrombectomy and soft debris removal device
US20090312663A1 (en) * 2008-06-13 2009-12-17 New York University System and Method for Neurometric Analysis
US20200163573A1 (en) * 2010-01-06 2020-05-28 Evoke Neurosceince, Inc. Electrophysiology measurement and training and remote databased and data analysis measurement method and system
CN103976740A (en) * 2014-05-23 2014-08-13 清华大学 Network environment-oriented electroencephalogram identification system and network environment-oriented electroencephalogram identification method
CN109846477A (en) * 2019-01-29 2019-06-07 北京工业大学 A kind of brain electricity classification method based on frequency band attention residual error network
CN110960233A (en) * 2019-11-21 2020-04-07 唐延智 Depression state detection method and system based on brain waves

Also Published As

Publication number Publication date
US20050251419A1 (en) 2005-11-10
US8239013B2 (en) 2012-08-07

Similar Documents

Publication Publication Date Title
US8239013B2 (en) EEG prediction method for medication response
EP1253853B1 (en) Method for classifying physiologic brain imbalances using quantitative eeg
O'Connor et al. Non‐surgical treatment (other than steroid injection) for carpal tunnel syndrome
US8509885B2 (en) S and M for analyzing and assessing depression and other mood disorders using electoencephalograhic (EEG) measurements
USRE46189E1 (en) Field deployable concussion assessment device
Marson et al. Carbamazepine versus valproate monotherapy for epilepsy
Vassiliadis et al. Factors influencing prehospital and emergency department analgesia administration to patients with femoral neck fractures
AU2001236794A1 (en) Method for classifying and treating physiologic brain imbalances using quantitative EEG
US20140155763A1 (en) Medical analysis and diagnostic system
Weisman et al. Practice changes in response to the malpractice litigation climate: results of a Maryland physician survey
Scuffham et al. Trends in cycle injury in New Zealand under voluntary helmet use
Hochberg Prevalence of systemic lupus erythematosus in England and Wales, 1981-2.
Milburn-McNulty et al. Sulthiame monotherapy for epilepsy
Mumford et al. An investigation of ‘functional’somatic symptoms among patients attending hospital medical clinics in Pakistan—II. Using somatic symptoms to identify patients with psychiatric disorders
Ly et al. National hospital ambulatory medical care survey: 1999 outpatient department summary
Jain et al. Juvenile myoclonic epilepsy: disease expression among Indian families
Japaridze et al. Implementing the SCORE system improves the quality of clinical EEG reading
Smith Jr et al. Assessing the effectiveness of mental health care in routine clinical practice: characteristics, development, and uses of patient outcomes modules
Cryer et al. Indicators for injury surveillance
Seeley Developing services for head injury: obtaining the data
Anninos et al. MEG measurements with SQUID as a diagnostic tool for epileptic patients
Jay et al. Quality of last doctor visit reports: a comparison of medical records and survey data
Tsai et al. Morbidity patterns among employees at a petroleum refinery
Veselá A Gnu Health Monitoring Module
WIEN Tbrno

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION